<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080793</url>
  </required_header>
  <id_info>
    <org_study_id>LEJEUNE-CORMIER INCA 2012</org_study_id>
    <nct_id>NCT02080793</nct_id>
  </id_info>
  <brief_title>STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS</brief_title>
  <acronym>CALIPSO</acronym>
  <official_title>STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      This study will be based on two questionnaires&#xD;
&#xD;
        1. One specific questionnaire that has already been developed from social sciences&#xD;
           interviews conducted in men who have been treated for localized prostrate cancer, with a&#xD;
           good or intermediate prognosis. This questionnaire comprises 11 pairs of scenarios. Each&#xD;
           scenario gathers in a random manner, the modalities of 7 possible characteristics of the&#xD;
           management strategy for localized prostrate cancer, with a good or intermediate&#xD;
           prognosis:&#xD;
&#xD;
             -  the risk of death at 5 years (modalities: 5%, 15%),&#xD;
&#xD;
             -  the risk of impotence (modalities: 0%, 25%, 50%, 75%),&#xD;
&#xD;
             -  the presence of urinary leaks (modalities: no protection during the day, one&#xD;
                protection pad per day, several protection pads per day),&#xD;
&#xD;
             -  the duration and frequency of care provided (modalities: 2 days of care in your&#xD;
                whole life, 7 days of care in your whole life, 5 half-days of care per week for 8&#xD;
                weeks, every 3 months for 2 years then every 6 months for life),&#xD;
&#xD;
             -  ablation of the prostate (modalities: Yes, No),&#xD;
&#xD;
             -  the existence of possible treatments in case of aggravation or recurrence&#xD;
                (modalities: Yes, No),&#xD;
&#xD;
             -  the nature of the technology used (modalities: innovative technology, standard&#xD;
                technology).&#xD;
&#xD;
           The objective is to ask each participant of the study for each pair of scenarios, to&#xD;
           choose from the two scenarios (binary-choice survey), the scenario he prefers.&#xD;
&#xD;
        2. The &quot;Spielberger Inventory Trait&quot; scale to evaluate stable characteristics in the&#xD;
           propensity to anxiety in study participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2013</start_date>
  <primary_completion_date type="Actual">June 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of personal factors linked to the management strategy chosen with regard to the preferences of patients.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">652</enrollment>
  <condition>Patients Seen at a Urology Consultation</condition>
  <arm_group>
    <arm_group_label>Patients phase pilote</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients phase réelle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <arm_group_label>Patients phase pilote</arm_group_label>
    <arm_group_label>Patients phase réelle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men:&#xD;
&#xD;
          -  aged 50 to 70 years&#xD;
&#xD;
          -  seen at a urology consultation&#xD;
&#xD;
          -  able to understand written and spoken French&#xD;
&#xD;
          -  who have provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Men:&#xD;
&#xD;
          -  under guardianship or wards of court&#xD;
&#xD;
          -  who have already been diagnosed withor treated for prostrate cancer&#xD;
&#xD;
          -  with recently diagnosed cancer or on treatment for this cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique St Marie</name>
      <address>
        <city>Chalon-sur-saone</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital TENON</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

